A Study of Adavosertib as Treatment for Uterine Serous Carcinoma
Public ClinicalTrials.gov record NCT04590248. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 2b study aims to evaluate the efficacy and safety of adavosertib, an inhibitor of the tyrosine kinase WEE1, in subjects with recurrent or persistent uterine serous carcinoma (USC) who have previously received at least 1 prior platinum-based chemotherapy regimen for the management of USC.
Study identification
- NCT ID
- NCT04590248
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 109 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2020 (Actual)
- Primary completion
- May 23, 2022 (Actual)
- Completion
- Feb 7, 2023 (Actual)
- Last update posted
- Aug 14, 2023
2020 – 2023
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Burbank | California | 91505 | — |
| Research Site | Duarte | California | 91010 | — |
| Research Site | La Jolla | California | 92093 | — |
| Research Site | West Hollywood | California | 90048 | — |
| Research Site | Aurora | Colorado | 80045 | — |
| Research Site | Iowa City | Iowa | 52242 | — |
| Research Site | Covington | Louisiana | 70433 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Research Site | New Brunswick | New Jersey | 08903 | — |
| Research Site | New York | New York | 10065 | — |
| Research Site | The Bronx | New York | 10467 | — |
| Research Site | Spokane | Washington | 99202 | — |
| Research Site | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04590248, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 14, 2023 · Synced Oct 31, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04590248 live on ClinicalTrials.gov.